Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : biotech insider buys -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (12)	1/22/2003 1:02:14 PM
From: fred hayes	Respond to of 213

My guess is that their subsidiary NeoGene is worth a whole lot more than the $3 mil current market cap of SPPI. But just a guess -- would defer to Erik for more reliable info. fred

To: tuck who wrote (12)	1/22/2003 1:26:21 PM
From: dalroi	Respond to of 213

if Erik sees something we indeed beter ask him cheers S

To: tuck who wrote (12)	1/22/2003 1:31:17 PM
From: Icebrg	Read Replies (3) \| Respond to of 213

>> had left them for dead, but Erik saw something, maybe we'd better ask him what.>> I saw the new management, i.e. Raj and Luigi. They don't have to do this if they don't want to. They could retire or work as overpaid consultants to big pharma. They have as far as I can see a very good reputation in the industry. Luigi was the godfather and promoter of Taxol while at Bristol. I saw (or rather heard about) managers who were foregoing their salaries to give their company a chance to survive. Normally it seems to be the other way around. I saw a surprisingly good deal with GP Biotech in principle ensuring the company's survival (although on a slow burn). Since then they have managed some piecemal stock issues from their shelf. It seems that at least some of the new investors are serious and some of them are coming back for more. And some of their suppliers agreed to be paid in stock rather than cash. There was almost no fumes left to run on. From some recent filings. Nov 21. Issue price USD 2.00 Cranshire Capital 188.000 L Lenaz 50.000 R Mital 200.000 Omicron Master Trust 200.000 Mark Wheeler 300.000 Dec 13. Issue price 2.10 Verticle Venture 199.500 Midsummer Capital 199.500 ICN Capital 199.500 Jan 16. Issue price 2.25 Cranshire Capital 200.000 Omicron Master Trust 200.000 ICN Capital 100.000 The L Lenanz is Luigi. Looking around on the net for the venture capitalists, I came across Michael Amsalem who seems to be or have been engaged both in Midsummer and Omicron. Michel Amsalem, founder and president of Midsummer Capital LLC and formerly managing partner of Omicron Capital, L.P. has over thirty years of experience in the origination, structuring, negotiation and management of investments in complex environments. He received his Doctorate from Harvard University’s Graduate School of Business and his MBA from Columbia University where he was also a Professor. He has since returned to teach business policy and strategy courses at Columbia as an Adjunct Professor. He is also a graduate of Ecole des Hautes Etudes Commerciales in France. pcnr.com Michel Amsalem Adjunct Professor Executive MBA Programs Diplôme, HEC, 1969; MBA, Columbia, 1972; DBA, Harvard, 1978. Teaching and research interests Professor Amsalem is the founder and managing director of Mimran Capital, an investment banking vehicle focused on investment and the delivery of corporate finance services to early- and growth-stage companies in emerging markets. He started his career in emerging markets finance at the International Finance Corporation, the private-sector arm of the World Bank, and later founded and managed Patricof Emerging Markets. He also managed the Latin American and Eastern European investment banks of Banque Indosuez and Citibank’s structured finance department, delivering corporate finance products in emerging countries. A full-time faculty member at the School from 1979 to 1985, Amsalem is the author of a book as well as a number of articles on emerging country economics and finance. www3.gsb.columbia.edu He looks solid and not stupid. As for the generic business. Well, that is perhaps too early to have an opinion on. Their Indian partner looks solid. They have just filed the first ANDA. And Raj isn't stupid either. Spectrum Pharmaceuticals Announces Filing of First ANDA With the FDA for Approval to Market Generic Drugs in the United States Wednesday January 15, 8:33 am ET Company Plans Additional Filings During 2003; Looks for Revenue From Generic Business During 2004 biz.yahoo.com Their first patient treated with Neoquin was lucky enough to register as a complete response. Purely anecdotal at this point, but at least very nice for him (or her). Spectrum Pharmaceuticals to Expand Study of Superficial Bladder Cancer Drug Wednesday December 11, 2:12 pm ET Complete Response in First Patient Treated Leads Company to Expand the Number of Clinical Sites and Accelerate Enrollment biz.yahoo.com The company has a market cap. of a little bit above 3 mUSD, so there should be some room to grow if they are successful. Dr. Tracy has said that he is going to continue to follow them (because of an interest from his readers), although they have at least for the time being left the CNS-field. (There is still one phase II trial using Neotrofin for the indication neuropathy un-reported). A Phase 2 study is currently ongoing in the U.S. for Chemotherapy-induced peripheral neuropathy. Enrollment has been completed for this study By and large. This story is almost like booting a computer. Creating something from (almost) nothing. I wish them well. To me they seem to deserve it. Erik

To: tuck who wrote (12)	2/3/2003 4:49:12 PM
From: Icebrg	Respond to of 213

The purchasing continues "unabated". Very strange - don't these people know how to award themselves options? The numbers are not big - on the contrary, they are diminutive. But what can one expect from people who don't receive any salary? (It has been claimed). Anyhow. Today Raj (CEO) files for another 3.200 shares. Luigi Lenaz (the cancer guy) for 1.000 and John McManus (the Finance person) for 1.000 shares. It might be difficult to buy more without moving the share price. This is indeed a thinly traded stock.